News Releases

Date Title and Summary View
Jan 30, 2020
Jan 29, 2020
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
Initiating Vaccine Development and Providing Supplies of Antiviral Medicines to China for Investigational Use NEW BRUNSWICK, N.J. , Jan. 29, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a
Jan 23, 2020
Jan 22, 2020
Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results:
- 2019 Fourth-Quarter Sales of $20.7 Billion reflecting growth of 1.7%, operational growth of 2.6%* and adjusted operational growth of 3.4%* - 2019 Full-Year Sales of $82.1 Billion reflecting growth of 0.6%, operational growth of 2.8%* and adjusted operational growth of 4.5%* - 2019 Fourth-Quarter
Jan 20, 2020
Jan 20, 2020
Jan 15, 2020
Jan 02, 2020
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020
NEW BRUNSWICK, N.J., Jan. 2, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2020 of $0.95 per share on the company's common stock. The dividend is payable on March 10, 2020 to shareholders of
Dec 30, 2019
Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
HORSHAM, Pa. , Dec. 30, 2019 /PRNewswire/ --   The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced today the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain
Dec 21, 2019
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.